Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on LinkedIn about a recent article by Julianne Cynthia de Ruiter et al, published in British Journal of Cancer
“The ES-LUNG group in the Netherlands publishes another update from their >2,100 patient non-randomized registry of stage I NSCLC treated with VATS lobectomy or SBRT. This latest report demonstrates an OS benefit of surgery in patients with a history of prior MI, and an OS benefit of SBRT when FEV1 and/or DLCO are <80%.
These data challenge the enthusiasm of recent reports heralding the safety of operating on patients with critical FEV1/DLCO values below 80%.”
Title: Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics
Authors: Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink
Read the Full Article on British Journal of Cancer
More posts featuring Drew Moghanaki.
